alexa Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases.


Journal of Surgery

Author(s): Cutuli B, LeNir CC, Serin D, Kirova Y, Gaci Z, , Cutuli B, LeNir CC, Serin D, Kirova Y, Gaci Z,

Abstract Share this page

Abstract BACKGROUND: Infiltrating MBC represents less than 1\% of all male cancers. Our study details clinico-pathological features, treatments and prognostic factors in a large French cohort. MATERIAL AND METHODS: Four hundred and eighty-nine patients were collected from 1990 to 2005. Median age was 66 years (34\% over 70 years) and median follow-up 58 months. RESULTS: According to TN classification, we found T(1): 39\%, T(2): 41\%, T(3)T(4): 9\%, T(x): 11\% and N(1)N(2): 27\%. Lumpectomy (L) and mastectomy (M) were performed in 8.6\% and 91.4\% of the cases. Axillary dissection (AD), sentinel node biopsy or both were performed in 90\%, 2\% and 5\% of the cases, respectively. Ninety-five percent of tumours were ductal carcinomas; 47\% were pT(1), 20\% pT(2) and 33\% pT(3)-T(4). Axillary nodal involvement was present in 52.8\% cases. ER and PgR were positive in 92\% and 89\% cases. Radiotherapy (RT) was performed in 85\% of the patients. Hormonal treatment (HT) was delivered in 72\% of the cases. Tamoxifen and aromatase inhibitors were used in 85\% and 12\% of the cases; 34\% of the patients received chemotherapy (CT). Local recurrence (LR), nodal recurrences (NR) and metastases occurred in 2\%, 5\% and 22\% of the cases; 2\% and 10\% developed contralateral BC and second cancer. The 5- and 10-year overall survival (OS) rates were 81\% and 59\%; disease-specific survivals (DSS) were 89\% and 72\%. Death causes were BC 56\%, second cancer 8\%, complications 3\%, intercurrent disease 15\% and unknown 18\%. In a univariate analysis, metastatic risk factors were T stage (T1: 19\%, T(2): 26\%, T(3)T(4): 40\%; p=0.013), pN status (pN(0): 12\% pN(1-3): 26\% pN(>3): 44\%; p<0.0001) and presence of locoregional recurrence (62\% versus 18\% p<0.0001). In a multivariate analysis, axillary nodal involvement and high SBR remain prognostic factors. CONCLUSION: Earlier diagnosis and wide use of adjuvant treatments (RT/HT/CT) widely decreased LR and increased survival rates in MBC, reaching female ones. Prognostic factors were also very similar to female ones. Copyright 2009 Elsevier Ireland Ltd. All rights reserved. This article was published in Crit Rev Oncol Hematol and referenced in Journal of Surgery

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version